8-K Announcements
6Material company update
Apr 20, 2026·SEC
Material company update
Mar 27, 2026·SEC
Material company update
Mar 3, 2026·SEC
AnaptysBio, Inc.(ANAB)Earnings, Financials & Key Ratios
ANAB•NASDAQ
$69.32
$2.99B mkt cap·Price updated May 6, 2026
AboutAnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.Show more
- Revenue$235M+157.0%
- EBITDA$50M+144.7%
- Net Income-$13M+90.9%
- EPS (Diluted)-0.46+91.0%
- Gross Margin98.97%+224.5%
- EBITDA Margin21.45%+117.4%
- Operating Margin20.42%+116.2%
- Net Margin-5.64%+96.5%
- ROE-24.49%+86.6%
- ROIC55.1%+223.7%
- Debt/Equity0.38-92.7%
- Interest Coverage0.60+131.6%
ANAB Key Insights
AnaptysBio, Inc. (ANAB) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 98 (top 2%)
- ✓Strong 5Y sales CAGR of 25.6%
- ✓Trading near 52-week high
✗Weaknesses
- ✗Shares diluted 10.4% in last year
- ✗Expensive at 58.4x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ANAB Price & Volume
AnaptysBio, Inc. (ANAB) stock price & volume — 10-year historical chart
Loading chart...
ANAB Growth Metrics
AnaptysBio, Inc. (ANAB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years29.58%
5 Years25.62%
3 Years183.58%
TTM157.01%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM90.89%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM90.11%
Return on Capital
10 Years-14.53%
5 Years-15.48%
3 Years-15.77%
Last Year12.54%
ANAB Recent Earnings
AnaptysBio, Inc. (ANAB) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 11/12 qtrs (92%)
Q2 2026Latest
Mar 3, 2026EPS
$1.58
Est $0.89
+77.5%
Revenue
$108M
Est $87M
+24.4%
Q4 2025
Nov 4, 2025EPS
$0.52
Est $1.06
+149.1%
Revenue
$76M
Est $22M
+248.2%
Q3 2025
Aug 7, 2025EPS
$1.34
Est $1.50
+10.7%
Revenue
$22M
Est $12M
+90.5%
Q3 2025
Aug 6, 2025EPS
$1.34
Est $1.50
+10.7%
Revenue
$22M
Est $21M
+6.9%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 3, 2026 | $1.58vs $0.89+77.5% | $108Mvs $87M+24.4% |
| Q4 2025 | Nov 4, 2025 | $0.52vs $1.06+149.1% | $76Mvs $22M+248.2% |
| Q3 2025 | Aug 7, 2025 | $1.34vs $1.50+10.7% | $22Mvs $12M+90.5% |
| Q3 2025 | Aug 6, 2025 | $1.34vs $1.50+10.7% | $22Mvs $21M+6.9% |
Based on last 12 quarters of dataView full earnings history →
ANAB Peer Comparison
AnaptysBio, Inc. (ANAB) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RCUS | 2.62B | 26.06 | -7.92 | -4.26% | -156.36% | -68.97% | 0.16 | |
 ARQT | 2.89B | 23.42 | -180.15 | 91.34% | -4.29% | -8.52% | 0.03 | |
 DAWN | 2.22B | 21.53 | -20.70 | 20.6% | -67.85% | -23.43% | 0.01 | |
 FOLD | 4.47B | 14.49 | -80.50 | 32.29% | -2.35% | -6.1% | 2.29 | |
 IMVT | 5.66B | 27.84 | -10.20 | -47.07% | 0.00 | |||
 REGN | 72.97B | 702.33 | 16.93 | 0.99% | 29.65% | 14.32% | 5.59% | 0.09 |
 ABBV | 364.63B | 206.15 | 86.98 | 8.57% | 6.91% | 62.15% | 4.89% | |
 LLY | 933.66B | 988.19 | 43.06 | 44.7% | 34.98% | 101.17% | 0.96% | 1.60 |
Compare ANAB vs Peers
AnaptysBio, Inc. (ANAB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ANAB Income Statement
AnaptysBio, Inc. (ANAB) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 10M | 5M | 8M | 75M | 63.17M | 10.29M | 17.16M | 91.28M | 234.6M |
| Revenue Growth % | -40.06% | -50% | 60% | 837.5% | -15.77% | -83.72% | 66.78% | 432.03% | 157.01% |
| Cost of Goods Sold | 29.44M | 56.2M | 99.34M | 80.03M | 98.5M | 88.8M | 132.28M | 163.84M | 2.42M |
| COGS % of Revenue | 294.43% | 1123.92% | 1241.72% | 106.7% | 155.91% | 863.21% | 771.01% | 179.49% | 1.03% |
| Gross Profit | -19.44M▲ 0% | -51.2M▼ 163.3% | -91.34M▼ 78.4% | -5.03M▲ 94.5% | -35.32M▼ 602.9% | -78.51M▼ 122.3% | -115.13M▼ 46.6% | -72.56M▲ 37.0% | 232.18M▲ 420.0% |
| Gross Margin % | -194.43% | -1023.92% | -1141.72% | -6.7% | -55.91% | -763.21% | -671.01% | -79.49% | 98.97% |
| Gross Profit Growth % | -1637% | -163.31% | -78.41% | 94.5% | -602.91% | -122.28% | -46.64% | 36.97% | 419.98% |
| Operating Expenses | 9.34M | 15.53M | 16.09M | 18.85M | 21.49M | 36.64M | 49.28M | 42.39M | 184.28M |
| OpEx % of Revenue | 93.38% | 310.52% | 201.18% | 25.14% | 34.02% | 356.21% | 287.26% | 46.44% | 78.55% |
| Selling, General & Admin | 9.34M | 15.53M | 16.09M | 18.85M | 21.49M | 36.64M | 41.95M | 42.39M | 50.74M |
| SG&A % of Revenue | 93.38% | 310.52% | 201.18% | 25.14% | 34.02% | 356.21% | 244.48% | 46.44% | 21.63% |
| Research & Development | 30.94M | 56.3M | 99.34M | 80.03M | 98.5M | 88.8M | 139.62M | 163.84M | 135.97M |
| R&D % of Revenue | 309.43% | 1125.92% | 1241.72% | 106.7% | 155.91% | 863.21% | 813.79% | 179.49% | 57.96% |
| Other Operating Expenses | -30.94M | -56.3M | -99.34M | -80.03M | -98.5M | -88.8M | -132.28M | -163.84M | -2.42M |
| Operating Income | -28.78M▲ 0% | -66.72M▼ 131.8% | -107.43M▼ 61.0% | -23.88M▲ 77.8% | -56.81M▼ 137.9% | -115.15M▼ 102.7% | -164.41M▼ 42.8% | -114.95M▲ 30.1% | 47.9M▲ 141.7% |
| Operating Margin % | -287.81% | -1334.44% | -1342.9% | -31.84% | -89.93% | -1119.41% | -958.27% | -125.93% | 20.42% |
| Operating Income Growth % | -851.44% | -131.83% | -61.01% | 77.77% | -137.92% | -102.69% | -42.77% | 30.08% | 141.67% |
| EBITDA | -28.6M | -66.41M | -106.92M | -23.32M | -54.72M | -112.82M | -163.76M | -112.55M | 50.32M |
| EBITDA Margin % | -285.98% | -1328.14% | -1336.48% | -31.09% | -86.62% | -1096.71% | -954.47% | -123.3% | 21.45% |
| EBITDA Growth % | -924.28% | -132.21% | -61% | 78.19% | -134.67% | -106.16% | -45.15% | 31.27% | 144.71% |
| D&A (Non-Cash Add-back) | 183K | 315K | 514K | 559K | 2.09M | 2.33M | 652K | 2.4M | 2.42M |
| EBIT | -28.3M | -60.2M | -96.45M | -19.93M | -57.8M | -107.59M | -157.07M | -95.14M | 47.9M |
| Net Interest Income | -152K | 5.03M | 9.94M | 3.96M | -1.02M | -13.56M | 790K | -30.29M | -66.39M |
| Interest Income | 1.62M | 6.68M | 10.98M | 3.96M | 431K | 7.55M | 18.87M | 19.79M | 13.5M |
| Interest Expense | 1.77M | 1.65M | 1.04M | 0 | 1.45M | 21.11M | 18.08M | 50.09M | 79.89M |
| Other Income/Expense | -1.29M | 4.87M | 9.94M | 3.95M | -982K | -13.55M | 788K | -30.28M | -60.96M |
| Pretax Income | -30.07M▲ 0% | -61.85M▼ 105.7% | -97.49M▼ 57.6% | -19.93M▲ 79.6% | -57.8M▼ 190.0% | -128.7M▼ 122.7% | -163.62M▼ 27.1% | -145.23M▲ 11.2% | -13.07M▲ 91.0% |
| Pretax Margin % | -300.7% | -1236.96% | -1218.6% | -26.57% | -91.49% | -1251.09% | -953.68% | -159.1% | -5.57% |
| Income Tax | 0 | -192K | -152K | 0 | 0 | 24K | -4K | 3K | 164K |
| Effective Tax Rate % | 0% | 0.31% | 0.16% | 0% | 0% | -0.02% | 0% | -0% | -1.25% |
| Net Income | -30.07M▲ 0% | -61.66M▼ 105.0% | -97.34M▼ 57.9% | -19.93M▲ 79.5% | -57.8M▼ 190.0% | -128.72M▼ 122.7% | -163.62M▼ 27.1% | -145.23M▲ 11.2% | -13.23M▲ 90.9% |
| Net Margin % | -300.7% | -1233.12% | -1216.7% | -26.57% | -91.49% | -1251.33% | -953.66% | -159.11% | -5.64% |
| Net Income Growth % | -606.03% | -105.04% | -57.87% | 79.52% | -189.98% | -122.72% | -27.11% | 11.24% | 90.89% |
| Net Income (Continuing) | -30.07M | -61.66M | -97.34M | -19.93M | -57.8M | -128.72M | -163.62M | -145.23M | -13.23M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.52▲ 0% | -2.50▼ 64.5% | -3.60▼ 44.0% | -0.73▲ 79.7% | -2.11▼ 189.0% | -4.57▼ 116.6% | -6.08▼ 33.0% | -5.12▲ 15.8% | -0.46▲ 91.0% |
| EPS Growth % | -560.87% | -64.47% | -44% | 79.72% | -189.04% | -116.59% | -33.04% | 15.79% | 91.02% |
| EPS (Basic) | -1.52 | -2.50 | -3.60 | -0.73 | -2.11 | -4.57 | -6.08 | -5.12 | -0.46 |
| Diluted Shares Outstanding | 19.78M | 24.67M | 27.06M | 27.3M | 27.43M | 28.16M | 26.92M | 28.38M | 31.34M |
| Basic Shares Outstanding | 19.78M | 24.67M | 27.06M | 27.3M | 27.43M | 28.16M | 26.92M | 28.38M | 27.79M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
ANAB Balance Sheet
AnaptysBio, Inc. (ANAB) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 252.7M | 434.22M | 377.73M | 396.56M | 553.88M | 447.2M | 406.83M | 431.88M | 350.25M |
| Cash & Short-Term Investments | 248.41M | 427.08M | 374.23M | 393.65M | 548.1M | 441.24M | 390.9M | 385.37M | 311.64M |
| Cash Only | 81.19M | 113.6M | 171.02M | 250.46M | 495.73M | 71.31M | 35.97M | 123.08M | 238.2M |
| Short-Term Investments | 167.22M | 313.49M | 203.21M | 143.2M | 52.37M | 369.93M | 354.94M | 262.29M | 73.44M |
| Accounts Receivable | 1.6M | 174K | 0 | 0 | 876K | 1.42M | 6.85M | 40.77M | 33.85M |
| Days Sales Outstanding | 58.44 | 12.7 | - | - | 5.06 | 50.35 | 145.75 | 163.01 | 52.66 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 4.54M | 9.08M | 5.74M | 4.76M |
| Total Non-Current Assets | 76.67M | 74.78M | 57.46M | 19.99M | 89.19M | 163.18M | 45.55M | 51.96M | 14.14M |
| Property, Plant & Equipment | 665K | 1.45M | 1.62M | 2.13M | 21.84M | 19.99M | 18.27M | 16.23M | 13.89M |
| Fixed Asset Turnover | 15.04x | 3.46x | 4.94x | 35.26x | 2.89x | 0.51x | 0.94x | 5.62x | 16.89x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 75.9M | 73.13M | 54.3M | 17.55M | 67.1M | 142.94M | 27.03M | 35.47M | 0 |
| Other Non-Current Assets | 106K | 208K | 1.54M | 318K | 256K | 256K | 256K | 256K | 256K |
| Total Assets | 329.36M▲ 0% | 509M▲ 54.5% | 435.2M▼ 14.5% | 416.55M▼ 4.3% | 643.07M▲ 54.4% | 610.38M▼ 5.1% | 452.39M▼ 25.9% | 483.83M▲ 7.0% | 364.39M▼ 24.7% |
| Asset Turnover | 0.03x | 0.01x | 0.02x | 0.18x | 0.10x | 0.02x | 0.04x | 0.19x | 0.64x |
| Asset Growth % | 429.69% | 54.54% | -14.5% | -4.28% | 54.38% | -5.08% | -25.88% | 6.95% | -24.69% |
| Total Current Liabilities | 14.09M | 21.84M | 29.54M | 19.82M | 16.1M | 26.05M | 37.44M | 45.43M | 38.63M |
| Accounts Payable | 2.32M | 5.44M | 16.24M | 4.22M | 1.74M | 2.78M | 4.7M | 4M | 3.87M |
| Days Payables Outstanding | 28.8 | 35.35 | 59.66 | 19.23 | 6.45 | 11.44 | 12.96 | 8.92 | 583.13 |
| Short-Term Debt | 6.88M | 7.57M | 1.38M | 0 | 0 | 0 | 0 | 0 | 2.08M |
| Deferred Revenue (Current) | 4.86M | 8.7M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.59M | 2.42M | 2.15M | 3.69M | 4.18M | 5.38M | 23.77M | 39.5M | 32.67M |
| Current Ratio | 17.93x | 19.89x | 12.79x | 20.01x | 34.40x | 17.16x | 10.87x | 9.51x | 9.07x |
| Quick Ratio | 17.93x | 19.89x | 12.79x | 20.01x | 34.40x | 17.16x | 10.87x | 9.51x | 9.07x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 7.69M | 796K | 654K | 0 | 270.54M | 322.23M | 326.84M | 367.54M | 288.56M |
| Long-Term Debt | 7.55M | 625K | 0 | 0 | 0 | 0 | 0 | 353.43M | 12.03M |
| Capital Lease Obligations | 0 | 0 | 654K | 0 | 19.45M | 17.81M | 16.04M | 14.11M | 0 |
| Deferred Tax Liabilities | -140K | -171K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 140K | 171K | 0 | 0 | 251.09M | 304.41M | 310.81M | 0 | 276.53M |
| Total Liabilities | 21.78M | 22.63M | 30.19M | 19.82M | 286.64M | 348.28M | 364.29M | 412.97M | 327.19M |
| Total Debt | 14.45M | 8.26M | 2.9M | 342K | 20.95M | 19.45M | 17.81M | 369.46M | 14.11M |
| Net Debt | -66.74M | -105.34M | -168.12M | -250.11M | -474.77M | -51.86M | -18.15M | 246.38M | -224.08M |
| Debt / Equity | 0.05x | 0.02x | 0.01x | 0.00x | 0.06x | 0.07x | 0.20x | 5.21x | 0.38x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | 0.28x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | -4.45x |
| Interest Coverage | -15.94x | -36.44x | -92.65x | - | -39.86x | -5.10x | -8.69x | -1.90x | 0.60x |
| Total Equity | 307.58M▲ 0% | 486.37M▲ 58.1% | 405.01M▼ 16.7% | 396.73M▼ 2.0% | 356.43M▼ 10.2% | 262.1M▼ 26.5% | 88.1M▼ 66.4% | 70.87M▼ 19.6% | 37.21M▼ 47.5% |
| Equity Growth % | 683.29% | 58.13% | -16.73% | -2.04% | -10.16% | -26.46% | -66.39% | -19.56% | -47.49% |
| Book Value per Share | 15.55 | 19.71 | 14.97 | 14.53 | 12.99 | 9.31 | 3.27 | 2.50 | 1.19 |
| Total Shareholders' Equity | 307.58M | 486.37M | 405.01M | 396.73M | 356.43M | 262.1M | 88.1M | 70.87M | 37.21M |
| Common Stock | 24K | 27K | 27K | 27K | 28K | 29K | 27K | 30K | 28K |
| Retained Earnings | -85.03M | -146.69M | -244.03M | -263.96M | -321.75M | -450.48M | -614.1M | -759.33M | -772.56M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -426K | -223K | 338K | -4K | -422K | -5.25M | -797K | 305K | -24K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ANAB Cash Flow Statement
AnaptysBio, Inc. (ANAB) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -19.44M | -48.51M | -69.52M | -14.16M | -45.92M | -73.59M | -120.8M | -135.34M | 19.7M |
| Operating CF Margin % | -194.38% | -970.12% | -868.96% | -18.88% | -72.69% | -715.4% | -704.09% | -148.27% | 8.4% |
| Operating CF Growth % | -115.26% | -149.54% | -43.32% | 79.64% | -224.36% | -60.26% | -64.15% | -12.03% | 114.55% |
| Net Income | -30.07M | -61.66M | -97.34M | -19.93M | -57.8M | -128.72M | -163.62M | -145.23M | 49.61M |
| Depreciation & Amortization | 183K | 315K | 514K | 559K | 2.09M | 2.33M | 2.38M | 2.4M | 2.42M |
| Stock-Based Compensation | 4.38M | 9.96M | 12.41M | 11.5M | 15.35M | 27.36M | 33.2M | 34.05M | 36.07M |
| Deferred Taxes | 1.38M | -1.23M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 619K | 646K | -1.96M | 487K | 1.93M | 18.6M | 7.56M | 39.77M | 12.31M |
| Working Capital Changes | 4.08M | 3.46M | 16.85M | -6.77M | -7.49M | 6.84M | -324K | -66.33M | -80.72M |
| Change in Receivables | 1.23M | 1.43M | 174K | 0 | -876K | -543K | 0 | -33.91M | 6.92M |
| Change in Inventory | -237.97M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 2.22M | 7.08M | 0 | 0 | -4.74M | 9.7M | 10.94M | -33.84M | -87.33M |
| Cash from Investing | -243.06M | -142.45M | 131.43M | 94.47M | 38.84M | -394.85M | 144.75M | 95.4M | 228.03M |
| Capital Expenditures | -290K | -1.06M | -805K | -569K | -1.37M | -358K | -807K | -358K | -87K |
| CapEx % of Revenue | 2.9% | 21.26% | 10.06% | 0.76% | 2.16% | 3.48% | 4.7% | 0.39% | 0.04% |
| Acquisitions | 290.9M | 347.54M | 0 | 0 | 0 | 394.49M | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -290.9M | -347.54M | 0 | 0 | 15K | -394.49M | 0 | 0 | 0 |
| Cash from Financing | 292.45M | 223.36M | -4.49M | -879K | 252.3M | 44.02M | -59.3M | 127.05M | -132.61M |
| Debt Issued (Net) | 0 | -6.88M | -7.5M | -1.38M | 0 | 0 | -11.73M | 34.77M | -76.8M |
| Equity Issued (Net) | 292.54M | 227.48M | 3.01M | 496K | 2.55M | 11.83M | -47.53M | 100.39M | -54.37M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | -50M | -456K | -68.63M |
| Other Financing | -84K | 2.76M | 0 | 0 | 249.75M | 32.19M | -43K | -8.1M | -1.45M |
| Net Change in Cash | 29.96M▲ 0% | 32.41M▲ 8.2% | 57.42M▲ 77.2% | 79.44M▲ 38.3% | 245.21M▲ 208.7% | -424.42M▼ 273.1% | -35.34M▲ 91.7% | 87.11M▲ 346.5% | 115.12M▲ 32.1% |
| Free Cash Flow | -19.73M▲ 0% | -49.57M▼ 151.3% | -70.32M▼ 41.9% | -14.73M▲ 79.1% | -47.29M▼ 221.1% | -73.95M▼ 56.4% | -121.61M▼ 64.4% | -135.69M▼ 11.6% | 19.61M▲ 114.5% |
| FCF Margin % | -197.28% | -991.38% | -879.03% | -19.63% | -74.85% | -718.88% | -708.79% | -148.66% | 8.36% |
| FCF Growth % | -117.27% | -151.26% | -41.87% | 79.06% | -221.11% | -56.39% | -64.44% | -11.58% | 114.45% |
| FCF per Share | -1.00 | -2.01 | -2.60 | -0.54 | -1.72 | -2.63 | -4.52 | -4.78 | 0.63 |
| FCF Conversion (FCF/Net Income) | 0.65x | 0.79x | 0.71x | 0.71x | 0.79x | 0.57x | 0.74x | 0.93x | -1.49x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ANAB Key Ratios
AnaptysBio, Inc. (ANAB) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -10.44% | -17.34% | -15.53% | -21.84% | -4.97% | -15.35% | -41.62% | -93.44% | -182.71% | -24.49% |
| Return on Invested Capital (ROIC) | - | -17.79% | -16.09% | -26.08% | -9.34% | -301.44% | -187.96% | -88.02% | -44.53% | 55.1% |
| Gross Margin | 7.58% | -194.43% | -1023.92% | -1141.72% | -6.7% | -55.91% | -763.21% | -671.01% | -79.49% | 98.97% |
| Net Margin | -25.53% | -300.7% | -1233.12% | -1216.7% | -26.57% | -91.49% | -1251.33% | -953.66% | -159.11% | -5.64% |
| Debt / Equity | 0.35x | 0.05x | 0.02x | 0.01x | 0.00x | 0.06x | 0.07x | 0.20x | 5.21x | 0.38x |
| Interest Coverage | -8.30x | -15.94x | -36.44x | -92.65x | - | -39.86x | -5.10x | -8.69x | -1.90x | 0.60x |
| FCF Conversion | 2.12x | 0.65x | 0.79x | 0.71x | 0.71x | 0.79x | 0.57x | 0.74x | 0.93x | -1.49x |
| Revenue Growth | -5.05% | -40.06% | -50% | 60% | 837.5% | -15.77% | -83.72% | 66.78% | 432.03% | 157.01% |
ANAB SEC Filings & Documents
AnaptysBio, Inc. (ANAB) SEC filings — annual & quarterly reports (10-K, 10-Q)
ANAB Frequently Asked Questions
AnaptysBio, Inc. (ANAB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
AnaptysBio, Inc. (ANAB) reported $234.6M in revenue for fiscal year 2025. This represents a 4179% increase from $5.5M in 2013.
AnaptysBio, Inc. (ANAB) grew revenue by 157.0% over the past year. This is strong growth.
AnaptysBio, Inc. (ANAB) reported a net loss of $13.2M for fiscal year 2025.
Dividend & Returns
AnaptysBio, Inc. (ANAB) has a return on equity (ROE) of -24.5%. Negative ROE indicates the company is unprofitable.
AnaptysBio, Inc. (ANAB) generated $19.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More ANAB
AnaptysBio, Inc. (ANAB) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates